{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-043353","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.637590+00:00","generated_at":"2026-06-17T04:03:09.740329+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protagonist Therapeutics announces $100M public offering of 5M shares at $20/share","bullets":["5,000,000 shares offered at $20.00 each; underwriters have 30-day option for 750,000 additional shares.","Gross proceeds expected ~$100M before underwriting discounts and expenses, closing April 10, 2023.","Underwriting syndicate led by J.P. Morgan, Jefferies, and Piper Sandler & Co.","Shares offered under effective shelf registration statement No. 333-266595."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-043353","json":"https://secwatch.observer/filing/0001104659-23-043353.json","markdown":"https://secwatch.observer/filing/0001104659-23-043353.md","text":"https://secwatch.observer/filing/0001104659-23-043353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923043353/0001104659-23-043353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923043353/tm2311339d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:03:09.740329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}